CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 306 enrolled
Drug / intervention
Referral to harm reduction servicesbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04427202
NCT04427202N/ACompleted
CompareCT.gov

Ending Transmission of HIV, HCV, and STDs and Overdose in Rural Communities of People Who Inject Drugs (ETHIC)

University of Chicago·interventional·Posted Jun 11, 2020·Updated Dec 12, 2024

In Brief

A clinical study evaluating Referral to harm reduction services for HIV and 3 related conditions. Completed, enrolled 306 participants across 2 sites.

Detailed Summary

This study will evaluate the referral to harm reduction services (HRS) including syringe services, naloxone overdose prevention, substance use treatment referral, HIV, HCV, and STD testing and referral and linkage to care through capacity building of existing programs through client services data.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Hepatitis C, Opioid-use Disorder, Injection Drug Use
CountriesUnited States
CollaboratorsSouthern Illinois University, Community Action Place, Inc., New York University, University of Illinois at Chicago, University of Washington, National Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 11, 2020
Enrollment StartAug 14, 2020
Primary CompletionAug 16, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.1 years ago

Interventions

Referral to harm reduction servicesbehavioral

Participants are referred to harm reduction services